查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1605923

轉移性肺腺癌治療市場、規模、佔有率、趨勢、行業分析報告：按治療、按最終用戶、按地區 - 2025-2034 年市場預測

Metastatic Lung Adenocarcinoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment, End User, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2034 年，全球轉移性肺腺癌治療市場規模預計將達到 141.7 億美元。該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

標靶治療和免疫療法的進步顯著改善了患者的治療效果、肺癌盛行率的增加以及對個人化醫療的需求不斷增長，推動了轉移性肺腺癌治療市場的成長。

專門針對特定基因突變（例如 EGFR 和 ALK）的新療法的開發將在未來幾年提供市場機會。趨勢表明，人們越來越關注聯合療法和生物標記驅動的方法，以提高治療效果。總體而言，隨著製藥公司大力投資研發以滿足新興市場患者群體不斷增長的需求，該市場預計將擴大。

轉移性肺腺癌治療市場報告亮點

在治療方面，免疫療法由於持久的反應和提高的生存率而在市場上佔據主導地位。標靶治療領域也出現了強勁成長，特別是對於已識別出 EGFR 等基因突變的患者。

從最終用戶來看，由於擁有先進的治療方案和綜合護理設施，醫院部門仍然是轉移性肺腺癌治療市場的最大股東。為了滿足對強化和個人化癌症治療日益增長的需求，專科診所部門正在快速成長。

由於大型製藥公司和先進的醫療基礎設施的存在，北美在全球轉移性肺腺癌治療市場中佔據主導地位。在癌症發生率上升和醫療保健投資增加的推動下，亞太地區是成長最快的市場。

阿斯特捷利康、羅氏、默克公司、百時美施貴寶、輝瑞公司、諾華公司、禮來公司、安進公司、賽諾菲公司、勃林格殷格翰公司、武田製藥公司、強生公司、艾伯維公司、拜耳公司和葛蘭素史克公司都是轉移性的是肺腺癌治療市場的主要參與者。

目錄

第1章簡介

第 2 章執行摘要

第3章研究方法

第 4 章轉移性肺腺癌治療的全球市場洞察

  • 市場快照
  • 轉移性肺腺癌治療市場動態
    • 促進因素和機會
      • 越來越重視標靶治療
      • 免疫療法的進展
    • 抑制因素和挑戰
      • 存活率低
  • PESTEL 分析
  • 轉移性肺腺癌治療市場的趨勢
  • 價值鏈分析
  • 新冠肺炎 (COVID-19) 影響分析

第5章轉移性肺腺癌治療的全球市場：依治療分類

  • 主要發現
  • 簡介
  • 化療
  • 標靶治療
  • 免疫治療
  • 治療
  • 其他

第 6 章全球轉移性肺腺癌治療市場：依最終使用者劃分

  • 主要發現
  • 簡介
  • 醫院
  • 專科診所
  • 其他

第7章全球轉移性肺腺癌治療市場：依地區

  • 主要發現
  • 簡介
    • 轉移性肺腺癌治療市場評估：地區，2020-2034 年
  • 北美
    • 北美：依治療方式劃分，2020-2034 年
    • 北美：依最終使用者劃分，2020-2034 年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲：依處理方式，2020-2034 年
    • 歐洲：依最終使用者劃分，2020-2034 年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 歐洲其他地區
  • 亞太地區
    • 亞太地區：依處理方式，2020-2034 年
    • 亞太地區：依最終使用者劃分，2020-2034 年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳大利亞
    • 其他亞太地區
  • 中東/非洲
    • 中東和非洲：依治療方式劃分，2020 年至 2034 年
    • 中東和非洲：按最終用戶劃分，2020-2034 年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲地區
  • 拉丁美洲
    • 拉丁美洲：依處理方式劃分，2020-2034 年
    • 拉丁美洲：依最終使用者劃分，2020-2034 年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區

第8章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第9章公司簡介

  • AstraZeneca
  • Roche
  • Merck & Co
  • Bristol-Myers Squibb
  • Pfizer
  • Novartis
  • Eli Lilly and Company
  • Amgen
  • Sanofi
  • Boehringer Ingelheim
  • Takeda Pharmaceutical Company
Product Code: PM5255

The global metastatic lung adenocarcinoma treatment market size is expected to reach USD 14.17 billion by 2034, according to a new study by Polaris Market Research. The report "Metastatic Lung Adenocarcinoma Treatment Market Size, Share, Trends, Industry Analysis Report: By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The metastatic lung adenocarcinoma treatment market growth can be attributed to advancements in targeted therapies and immunotherapies that are significantly improving patient outcomes, increasing prevalence of lung cancer, and the rising demand for personalized medicine.

The development of novel treatment options, particularly those targeting specific genetic mutations such as EGFR and ALK, would offer opportunities for the market in the coming years. Trends indicate a growing focus on combination therapies and biomarker-driven approaches to enhance treatment efficacy. Overall, the market is expected to expand as pharmaceutical companies invest heavily in research and development to meet the evolving needs of this patient population.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

Based on treatment, the immunotherapy segment dominates the market due to its ability to provide durable responses and improved survival rates. The targeted therapy segment is also seeing significant growth, particularly in patients with identifiable genetic mutations such as EGFR.

In terms of end users, the hospital segment remains the largest shareholder in the metastatic lung adenocarcinoma treatment market, driven by the availability of advanced treatment options and comprehensive care facilities. The specialty clinics segment is growing rapidly, catering to the increasing demand for focused and personalized cancer treatment.

North America dominates the global metastatic lung adenocarcinoma treatment market, attributed to the presence of major pharmaceutical companies and advanced healthcare infrastructure. Asia Pacific is the fastest-growing market, propelled by rising cancer incidence rates and increasing healthcare investments.

AstraZeneca, Roche, Merck & Co., Bristol-Myers Squibb, Pfizer, Novartis, Eli Lilly and Company, Amgen, Sanofi, Boehringer Ingelheim, Takeda Pharmaceutical Company, Johnson & Johnson, AbbVie, Bayer, and GlaxoSmithKline are among the key players in the metastatic lung adenocarcinoma treatment market.

Polaris Market Research has segmented the metastatic lung adenocarcinoma treatment market report on the basis of treatment, end user, and region:

By Treatment Outlook (Revenue - USD Billion, 2020-2034)

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Others

By End User Outlook (Revenue - USD Billion, 2020-2034)

  • Hospitals
  • Specialty Clinics
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Metastatic Lung Adenocarcinoma Treatment Market Insights

  • 4.1. Metastatic Lung Adenocarcinoma Treatment Market - Market Snapshot
  • 4.2. Metastatic Lung Adenocarcinoma Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased Focus on Targeted Therapies
      • 4.2.1.2. Advancements in Immunotherapy
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Low Survival Rates
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Metastatic Lung Adenocarcinoma Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 5.4. Targeted Therapy
    • 5.4.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
  • 5.5. Immunotherapy
    • 5.5.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
  • 5.6. Therapy
    • 5.6.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 6.3. Hospitals
    • 6.3.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Hospitals, by Region, 2020-2034 (USD Billion)
  • 6.4. Specialty Clinics
    • 6.4.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Specialty Clinics, by Region, 2020-2034 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Metastatic Lung Adenocarcinoma Treatment Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Metastatic Lung Adenocarcinoma Treatment Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Metastatic Lung Adenocarcinoma Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Metastatic Lung Adenocarcinoma Treatment Market - North America
    • 7.3.1. North America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.3.2. North America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.3.3. Metastatic Lung Adenocarcinoma Treatment Market - U.S.
      • 7.3.3.1. U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.3.4. Metastatic Lung Adenocarcinoma Treatment Market - Canada
      • 7.3.4.1. Canada: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.4. Metastatic Lung Adenocarcinoma Treatment Market - Europe
    • 7.4.1. Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.3. Metastatic Lung Adenocarcinoma Treatment Market - UK
      • 7.4.3.1. UK: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.4. Metastatic Lung Adenocarcinoma Treatment Market - France
      • 7.4.4.1. France: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.5. Metastatic Lung Adenocarcinoma Treatment Market - Germany
      • 7.4.5.1. Germany: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.6. Metastatic Lung Adenocarcinoma Treatment Market - Italy
      • 7.4.6.1. Italy: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.7. Metastatic Lung Adenocarcinoma Treatment Market - Spain
      • 7.4.7.1. Spain: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.8. Metastatic Lung Adenocarcinoma Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.9. Metastatic Lung Adenocarcinoma Treatment Market - Russia
      • 7.4.9.1. Russia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.4.10. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.5. Metastatic Lung Adenocarcinoma Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.3. Metastatic Lung Adenocarcinoma Treatment Market - China
      • 7.5.3.1. China: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.4. Metastatic Lung Adenocarcinoma Treatment Market - India
      • 7.5.4.1. India: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.5. Metastatic Lung Adenocarcinoma Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.6. Metastatic Lung Adenocarcinoma Treatment Market - Japan
      • 7.5.6.1. Japan: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.7. Metastatic Lung Adenocarcinoma Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.8. Metastatic Lung Adenocarcinoma Treatment Market - South Korea
      • 7.5.8.1. South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.9. Metastatic Lung Adenocarcinoma Treatment Market - Australia
      • 7.5.9.1. Australia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.5.10. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.6. Metastatic Lung Adenocarcinoma Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.3. Metastatic Lung Adenocarcinoma Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.4. Metastatic Lung Adenocarcinoma Treatment Market - UAE
      • 7.6.4.1. UAE: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.5. Metastatic Lung Adenocarcinoma Treatment Market - Israel
      • 7.6.5.1. Israel: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.6. Metastatic Lung Adenocarcinoma Treatment Market - South Africa
      • 7.6.6.1. South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.6.7. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • 7.7. Metastatic Lung Adenocarcinoma Treatment Market - Latin America
    • 7.7.1. Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.3. Metastatic Lung Adenocarcinoma Treatment Market - Mexico
      • 7.7.3.1. Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.3.2. Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.4. Metastatic Lung Adenocarcinoma Treatment Market - Brazil
      • 7.7.4.1. Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.4.2. Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.5. Metastatic Lung Adenocarcinoma Treatment Market - Argentina
      • 7.7.5.1. Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.5.2. Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
    • 7.7.6. Metastatic Lung Adenocarcinoma Treatment Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
      • 7.7.6.2. Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AstraZeneca
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Roche
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Merck & Co
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bristol-Myers Squibb
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Pfizer
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Novartis
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Eli Lilly and Company
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Amgen
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Sanofi
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Boehringer Ingelheim
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Takeda Pharmaceutical Company
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development

List of Tables:

  • Table 1 Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 2 Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 3 North America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 4 North America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 5 U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 6 U.S.: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 7 Canada: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 8 Canada: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 9 Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 10 Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 11 UK: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 12 UK: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 13 France: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 14 France: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 15 Germany: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 16 Germany: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 17 Italy: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 18 Italy: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 19 Spain: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 20 Spain: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 21 Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 22 Netherlands: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 23 Russia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 24 Russia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 25 Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 26 Rest of Europe: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 27 Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 28 Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 29 China: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 30 China: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 31 India: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 32 India: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 33 Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 34 Malaysia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 35 Japan: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 36 Japan: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 37 Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 38 Indonesia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 39 South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 40 South Korea: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 41 Australia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 42 Australia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 43 Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 44 Rest of Asia Pacific: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 45 Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 46 Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 47 Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 48 Saudi Arabia: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 49 UAE: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 50 UAE: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 51 Israel: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 52 Israel: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 53 South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 54 South Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 55 Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 56 Rest of Middle East & Africa: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 57 Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 58 Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 59 Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 60 Mexico: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 61 Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 62 Brazil: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 63 Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 64 Argentina: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2020-2034 (USD Billion)
  • List of Figures:
  • Figure 1. Global Metastatic Lung Adenocarcinoma Treatment Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Metastatic Lung Adenocarcinoma Treatment Market, by Treatment, 2024 & 2034 (USD Billion)
  • Figure 8. Market by End User
  • Figure 9. Global Metastatic Lung Adenocarcinoma Treatment Market, by End User, 2024 & 2034 (USD Billion)